|
|
|
|
The PIs have emerged as critical drugs for people with HIV infection. Optimal sue involves combination with reverse transcriptase inhibitors. Resistance develops to each agent,and cross-resistance is likely.These agents must be used at full doses with attention to ensuring patient compliance.The expense of these agents may be offset by forestalling disease progression and death and returning people to productive life. Selecting the initial PI must be individualized,and factors to consider include proven activity,possible toxicities,dosing regimens,drug interactions,and costs. |
|